Sandoz Asks Fed. Circ. To Wipe Out Allergan's $39M IP Award
The Federal Circuit is being asked to weigh in on whether the company behind a popular eyebrow growth drug should have scored a $39 million verdict against Novartis' spun-off generic-drug making...To view the full article, register now.
Already a subscriber? Click here to view full article